Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial

Background There are limited options currently recommended in National Institute for Health and Care Excellence guidelines for the treatment of bipolar depression. Pramipexole has been shown to improve mood symptoms in two small pilot studies in such patients. Objectives Primary: to evaluate the cli...

Descrición completa

Detalles Bibliográficos

Principais autores:	Hamish McAllister-Williams, Nicola Goudie, Lumbini Azim, Victoria Bartle, Michael Berger, Chrissie Butcher, Thomas Chadwick, Emily Clare, Paul Courtney, Lyndsey Dixon, Nichola Duffelen, Tony Fouweather, William Gann, John Geddes, Sumeet Gupta, Beth Hall, Timea Helter, Paul Hindmarch, Eva-Maria Holstein, Ward Lawrence, Phil Mawson, Iain McKinnon, Adam Milne, Aisling Molloy, Abigail Moore, Richard Morriss, Anisha Nakulan, Judit Simon, Daniel Smith, Bryony Stokes-Crossley, Paul Stokes, Andrew Swain, Zoë Walmsley, Christopher Weetman, Allan H Young, Stuart Watson
Formato:	Artigo
Idioma:	Inglês
Publicado:	NIHR Journals Library 2025-05-01
Series:	Health Technology Assessment
Assuntos:	pramipexole treatment-resistant bipolar depression bipolar disorder bipolar depression depression adults randomised controlled trial placebo controlled multisite treatment outcome quality of life economic evaluation qualitative ppi psychiatry health economics
Acceso en liña:	https://doi.org/10.3310/HBFC1953
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!